TABLE OF CONTENTS
Volume 6, Issue 3 (May 2009)
Original Articles |
US Case Reports |
EU Case Reports |
US Legal and Regulatory Update |
EU Legal and Regulatory Update |
Patent Focus
Editorial
The need to create a balanced system: How to discourage abuse by IP holders and patent infringement FREE
Maria Fabiana Jorge Managing Editor
J Generic Med 6: 181-183; doi:10.1057/jgm.2009.17
Original Articles
Access to medicines, health and trade
Pascal Lamy
J Generic Med 6: 184-187; doi:10.1057/jgm.2009.11
Patients must have immediate access to affordable generic medicines at day one after patent expiry: The EGA response to the public consultation 'DG Competition Pharmaceutical Sector Inquiry: Preliminary Report'
European Generic medicines Association(EGA)
J Generic Med 6: 188-192; doi:10.1057/jgm.2009.9
Generics at the crossroads: Will Europe lead the way forward?
Eric Gorka
J Generic Med 6: 193-205; doi:10.1057/jgm.2009.10
All costs, no benefits: How the US–Jordan free trade agreement affects access to medicines
Rohit Malpani
J Generic Med 6: 206-217; doi:10.1057/jgm.2009.13
Pushing the limits of IP protection for pharmaceuticals via the Special 301 Report: The Israel experience
Tal Band
J Generic Med 6: 218-229; doi:10.1057/jgm.2009.19
Despite global downturn, generics makers stand to reap great rewards in China's evolving pharmaceutical market
Mandy Chui
J Generic Med 6: 230-236; doi:10.1057/jgm.2009.7
A follow-on biological drug is not a biogeneric: Lessons from Omnitrope and Valtropin
Robert I Roth and Nicholas M Fleischer
J Generic Med 6: 237-245; doi:10.1057/jgm.2009.8
Malaysian pharmaceutical industry: Opportunities and challenges
Mohamed Azmi Hassali, Kah Hay Yuen, Mohamed Izham Mohamed Ibrahim, Jia Woei Wong, Bee Hong Ng and David Sue San Ho
J Generic Med 6: 246-252; doi:10.1057/jgm.2009.12
US Case Reports
Merck v Apotex and its aftermath: Did Apotex have the last laugh?
Frederick H Rein and Joseph B Crystal
J Generic Med 6: 253-263; doi:10.1057/jgm.2009.15
EU Case Reports
House of Lords revisits 'Biogen' insufficiency; Novartis' fluvastatin patent obvious; High Court finds patent for slow release formulation valid but not infringed
Michael Burdon, Jade MacIntyre, James Armstrong and Rebecca Singleton
J Generic Med 6: 264-271; doi:10.1057/jgm.2009.16
US Legal and Regulatory Update
Does the patent office really believe delay occurs before it actually occurs? The effect of Wyeth et al v. Dudas on patent term adjustments
Nathan J Bailey
J Generic Med 6: 272-278; advance online publication, March 17, 2009; doi:10.1057/jgm.2009.6
EU Legal and Regulatory Update
Pharmaceutical; trademark; news
Richard Milchior and Estelle Benattar
J Generic Med 6: 279-283; advance online publication, May 12, 2009; doi:10.1057/jgm.2009.14
